<DOC>
	<DOCNO>NCT02626208</DOCNO>
	<brief_summary>This clinical trial investigate new vaginal delivery system make silicone rubber , contain Nestorone® , 19—nor progesterone derivative low dose serum estradiol ( E2 ) . The investigator plan evaluate one-month data serum estradiol ( E2 ) level three different contraceptive vaginal ring contain fix dose NES escalate dos ( 75 µg/day , 100 µg/day , 200 µg/day ) estradiol basis select CVR large contraceptive efficacy trial .</brief_summary>
	<brief_title>Dose Finding Study Contraceptive Vaginal Ring With Different Estradiol Levels Combination With Nestorone</brief_title>
	<detailed_description>This dose-finding study aim evaluate serum estradiol level use contraceptive vaginal ring release Nestorone® escalate dos estradiol normal cycling woman . The primary objective evaluate one-month data serum estradiol ( E2 ) level three different contraceptive vaginal ring contain fix dose Nestorone® ( NES ) escalate dos estradiol basis select contraceptive vaginal ring ( CVR ) dose contraceptive efficacy trial . The secondary objective evaluate effect three different estradiol dose NES- E2 CVR progesterone level , bleed side effect one month use evaluate effect hormone-free internal bleeding pattern . Nestorone serum level measure indication compliance continuous use ring .</detailed_description>
	<mesh_term>ST 1435</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>1 . Good general overall health chronic medical condition result periodic exacerbation require significant medical care . 2 . Age 1839 year , inclusive , enrollment visit . 3 . Have regular menstrual cycle 2135 day duration use hormonal contraception 4 . Have intact uterus ovary . 5 . Able willing comply protocol sign inform consent . 6 . Consistent use effective contraception precede cycle ( note : woman use oral , transdermal , vaginal , implantable intrauterine hormonal contraceptive precede cycle must discontinue least 7 day prior start treatment unprotected intercourse since discontinue method ) . 7 . Not high risk pregnancy , define consistently use nonhormonal method contraception ( include Copper IUDs ) ; surgically sterile male partner vasectomy ; abstinent ; samesex relationship start treatment study exit ( include recovery period ) . 8 . Have negative pregnancy test admission visit . 9 . Have diastolic blood pressure ( BP ) ≤85 mm Hg systolic BP ≤135 mm Hg 5 minute rest sit position admission visit . 10 . Willing abstain use nonwater base vaginal lubricant study . 1 . Participating another clinical trial involve investigational product within last 30 day ( prior screening ) planning participate another clinical trial study . 2 . Not live catchment area study site . 3 . Known hypersensitivity progestins estrogen . 4 . Contraindications combine estrogenprogestin contraceptive use include : Thrombophlebitis thromboembolic disorder . Past personal history deep vein thrombophlebitis thromboembolic disorder . History venous thrombosis embolism firstdegree relative &lt; 55 year age suggest familial defect blood coagulation system . History thrombosis embolism OR personal family history opinion investigator suggest increase risk . History stroke . Known suspected carcinoma breast . Carcinoma endometrium know suspected estrogendependent neoplasia . Undiagnosed abnormal genital bleeding . Cholestatic jaundice pregnancy jaundice prior hormonal contraceptive use . Hepatic adenoma carcinoma . Known suspected pregnancy . Smoking woman 35 year 35 year course trial ; woman &lt; 35 year smoke 15 cigarette per day must evaluate investigator inclusion base risk factor would increase risk cardiovascular disease ( CVD ) thromboembolism , e.g . lipid level , glucose level , BP , BMI , family history CVD young age . History retinal vascular lesion , unexplained partial complete loss vision . Headaches focal neurological symptom ( e.g. , migraine aura ) . 5 . Desire become pregnant study . 6 . Breastfeeding . 7 . Undiagnosed vaginal discharge vaginal lesion abnormality . Subjects diagnose screen Chlamydia gonococcus infection may include trial follow treatment ; partner treatment also recommend . Subjects vaginal infection ( yeast , trichomonis , bacterial vaginosis ) may enrol treatment . Investigators make determination subject high risk reinfection , e.g . multiple sex partner , untreated partner , whether subject include . In accordance PI/medical designee assessment local standard practice , woman history genital herpes include outbreaks infrequent . 8 . A know clinically significant Pap test abnormality , manage current local national guideline require treatment study participation . 9 . Known benign malignant liver tumor ; know active liver disease . 10 . Invasive cancer ( past history carcinoma sarcoma , except nonmelanoma skin cancer ) . 11 . Current past medically diagnose severe depression , , opinion investigator , could exacerbate use hormonal contraceptive . 12 . Known suspected current alcoholism drug abuse . 13 . Elevated serum fast clinical chemistry value complete blood count ( CBC ) value designate clinically significant investigator medically qualify subinvestigator . 14 . Uncontrolled thyroid disease . 15 . Known impaired hypothalamicpituitaryadrenal reserve . 16 . Body mass index ( BMI ) &gt; 35 . 17 . Use injectable contraceptive ( e.g . cyclofem depomedroxyprogesterone acetate ) 9 month prior enrollment spontaneous menses since last injection . 18 . Use oral , transdermal , vaginal , implantable intrauterine contraceptive within 7 day prior start treatment cycle . ( Copper IUD allowable . Levonorgestrel release IUD allow . ) NOTE : Discontinuation method must personal reason unrelated purpose enrollment study . 19 . Known hypersensitivity silicone rubber . 20 . History toxic shock syndrome . 21 . Cystoceles rectoceles anatomical abnormality would preclude use vaginal ring . 22 . Planning undergo major surgery study participation . 23 . Severe constipation . 24 . Use liver enzyme inducer inhibitor regular basis . 25 . Known HIV infection . 26 . Bariatric surgery within past year prior enrollment . Have issue concern ( judgment investigator ) may compromise safety subject confound reliability compliance information acquire study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Contraceptive vaginal ring</keyword>
</DOC>